AACR19: LOXO-195 shows promise as therapy for tumors with acquired NTRK resistance

Written by Rachel Jenkins, Future Science Group

Credit: Sheheryar Kabraji, Sridhar Ramaswamy Recently presented at the American Association for Cancer Research (AACR) Annual Meeting (Atlanta, GA, USA, 29 March–3 April 2019); a Phase I clinical trial and US FDA expanded access program investigated LOXO-195, a next-generation TRK inhibitor designed to block TRK activity in acquired NTRK resistance mutation tumors. “NTRK gene fusions, which cause heightened activity of TRK proteins, are detected in a wide range of cancer types,” explained David Hyman (Memorial Sloan Kettering Cancer Center). “Unfortunately, most tumors that initially respond eventually become resistant to first-generation TRK inhibitors like larotrectinib.” The study included 20 patients receiving LOXO-195...

To view this content, please register now for access

It's completely free